BloodFlow
AI platform integrating into hospital EHRs for real-time blood test interpretations.
Website: https://www.bloodflow.eu
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Company Name | BloodFlow |
| Tagline | AI platform integrating into hospital EHRs for real-time blood test interpretations. |
| Headquarters | Lisbon, Portugal |
| Founded | 2024 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed Funding | €1.2M [Portugal Startup News, July 2025] |
Links
PUBLIC
- Website. https://websummit.com/appearances/lis25/4b90f19b-94d6-4b6a-826b-8e7ae176a170/bloodflow/ [Web Summit, 2025]
- LinkedIn. https://www.linkedin.com/company/bloodflow2024 [LinkedIn, 2025]
- GitHub. https://github.com/tiagodccosta [GitHub, 2026]
Executive Summary
PUBLIC BloodFlow is a Lisbon-based healthtech startup that has secured seed funding to deploy an AI platform for real-time clinical interpretation of blood tests directly within hospital electronic health record (EHR) systems [Portugal Startup News, July 2025]. The company's immediate relevance stems from its focus on a high-volume, routine diagnostic workflow and its reported on-premise deployment model. This model addresses critical data privacy concerns in European healthcare [Perplexity Sonar Pro Brief, 2025].
Founded in October 2024 by solo founder Tiago Costa, the company's origins are in a self-built prototype developed while Costa finished his computer engineering degree [The Next Big Idea, 2025]. The core product is an API that integrates via the HL7 FHIR standard. It aims to transform raw lab results into explainable insights for clinicians without data leaving hospital infrastructure [Perplexity Sonar Pro Brief, 2025].
Costa's background combines software engineering with a history as a former high-performance athlete for Sporting CP. This narrative has been highlighted in local press. It does not yet include prior healthtech or commercial leadership experience [ECO, July 2025]. The business model is B2B, targeting hospital systems as primary customers. Future ambitions include pharmaceutical trials [Portugal Startup News, July 2025].
In July 2025, the company closed a €1.2 million seed round led by the Lisbon-based private equity firm 3xP Global. Capital is earmarked for team expansion and pursuing medical device certifications [3xP Global, July 2025]. Over the next 12-18 months, key milestones to watch will be the announcement of initial hospital pilot deployments. Progress on regulatory pathways matters too. So does scaling the technical and commercial teams beyond the founder.
Data Accuracy: YELLOW -- Core funding and product claims are reported by multiple Portuguese outlets, but customer traction and technical validation are not publicly available.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed |
Company Overview
PUBLIC
BloodFlow is a Lisbon-based healthtech startup founded in October 2024. The company's founding story, as reported by local media, is one of solo execution. Tiago Costa, a computer engineering graduate, reportedly built the first version of the platform alone in his parents' home while finishing his degree and working full-time [The Next Big Idea, 2025]. Costa is also a former high-performance athlete with Sporting CP [ECO, July 2025]. This background has been highlighted in coverage of the company's seed funding.
The company's first major external milestone was a €1.2 million seed financing round announced in July 2025. The round was led by the Health Innovation Fund of 3xP Global, a Lisbon-based private equity and venture firm [Portugal Startup News, July 2025]. The capital is intended for team expansion, market entry, and pursuing necessary regulatory certifications for medical devices [3xP Global, July 2025].
Data Accuracy: YELLOW -- Key founding details and funding amount sourced from Portuguese business press and investor announcement; founder background corroborated across multiple local outlets.
Product and Technology
MIXED
BloodFlow's core proposition is an AI platform designed to integrate directly into hospital electronic health record (EHR) systems. It aims to automate the interpretation of routine blood test results. The platform is described as a plug-and-play API that connects via the HL7 FHIR interoperability standard, a common protocol in healthcare IT. It is engineered to run fully on-premise to keep patient data within hospital infrastructure [Perplexity Sonar Pro Brief, 2025]. The intended output is real-time, explainable insights delivered to clinicians. This should save physician time and reduce diagnostic errors [Portugal Startup News, July 2025].
Public descriptions focus on the application layer and deployment model rather than the underlying AI technology. The company's GitHub profile, linked to founder Tiago Costa, lists a project titled 'Automating Blood Tests Analysis with Artificial Intelligence.' The repository does not specify the models, training data, or validation methodology [GitHub, 2026]. The emphasis on explainability suggests the system may generate reasoning alongside its interpretations. This is a critical feature for clinical adoption, though the technical approach to achieving this is not detailed.
- Primary surface. The product is marketed as an API-first solution for hospitals, with a wedge into blood diagnostics.
- Deployment model. A fully on-premise architecture is a stated requirement. It addresses data privacy concerns common in healthcare [Perplexity Sonar Pro Brief, 2025].
- Expansion intent. Public announcements indicate plans to expand the platform's use cases to support pharmaceutical clinical trials and pursue medical device certification. These are future roadmap items, not current product features [Portugal Startup News, July 2025].
No live customer deployments, case studies, or performance benchmarks (e.g., accuracy rates, integration timelines) have been publicly disclosed. The technology remains at an early stage. Its commercial readiness and regulatory pathway are yet to be demonstrated.
Data Accuracy: YELLOW -- Product claims are sourced from press releases and a brief; technical implementation details are not independently verified.
Market Research and Opportunity
PUBLIC
The market for AI-powered clinical decision support in diagnostics is expanding. It is driven by a global push to reduce physician burnout and standardize care pathways while managing rising patient volumes.
A third-party sizing for the specific AI blood test interpretation segment is not publicly available. However, analogous market data provides a reference point. The broader AI in medical diagnostics market was valued at approximately $1.5 billion in 2023. It is projected to grow at a compound annual rate of around 30% through 2030, according to a report from Grand View Research [Grand View Research, 2023]. The demand drivers cited in coverage of BloodFlow's space are consistent with this broader trend. These include a persistent shortage of clinical specialists, the administrative burden of interpreting high volumes of routine tests, and a growing emphasis on value-based care that rewards accuracy and efficiency [Portugal Startup News, July 2025].
Key adjacent markets that could serve as expansion vectors or competitive substitutes include laboratory information management systems (LIMS), broader clinical decision support software integrated within EHRs, and direct-to-consumer wellness platforms offering blood test analysis. The regulatory environment is a critical macro force. In Europe, achieving a CE Mark as a medical device is a significant hurdle that dictates market access and sales cycles. BloodFlow has stated an intent to pursue this certification [3xP Global, July 2025]. Data privacy regulations like the GDPR in Europe and HIPAA in the U.S. create a technical requirement for on-premise or highly secure cloud deployments. This aligns with the company's stated architecture [Perplexity Sonar Pro Brief, 2025].
AI in Medical Diagnostics (2023) | 1.5 | $B
Projected CAGR (2023-2030) | 30 | %
The projected growth rate for the broader diagnostic AI category suggests a receptive environment for new solutions. It does not guarantee success for any single entrant, though. The regulatory and data privacy requirements function as both a barrier to entry and a potential moat for compliant players.
Data Accuracy: YELLOW -- Market sizing is based on an analogous, broader sector report. Demand drivers and regulatory context are cited from company and investor announcements.
Competitive Landscape
MIXED BloodFlow enters a healthtech segment defined by a crowded field of AI-driven diagnostic aids. Its primary challenge is to carve out a defensible position against both specialized startups and broader clinical workflow platforms.
The competitive map must therefore be constructed from the broader category dynamics.
In the segment for AI-powered blood test analysis, competition unfolds across three tiers. First, specialized diagnostic AI startups like Kantesti, BloodGPT, and Hathr.ai likely represent the most direct threat. They compete for the same hospital IT budget and clinician attention. Second, large, horizontal clinical decision support and EHR vendors, such as Epic with its cognitive computing module or Cerner's HealtheIntent, offer integrated analytics that could be extended into hematology. This presents a substitution risk. Third, adjacent substitutes include traditional laboratory information systems (LIS) and manual interpretation workflows. BloodFlow aims to displace these by offering speed and explainability [Perplexity Sonar Pro Brief, 2025].
BloodFlow's claimed defensible edge today rests on two technical choices: its plug-and-play API for HL7 FHIR standards and its fully on-premise deployment model [Perplexity Sonar Pro Brief, 2025]. For European hospitals with strict data sovereignty requirements, the promise of zero patient data leaving infrastructure is a significant procurement consideration. However, this edge is perishable. The technical implementation of FHIR APIs is becoming table stakes. The on-premise model, while a current differentiator, could become a scaling bottleneck if cloud-based, multi-tenant architectures prove more efficient for larger health systems.
The company is most exposed in two areas. It lacks a disclosed commercial footprint. This puts it behind any competitor with live hospital deployments and referenceable customers. Its solo founder structure and lack of disclosed domain expertise in regulatory affairs or clinical sales create an execution gap. A competitor with a seasoned commercial team from the medtech or pharma sectors could outpace BloodFlow in navigating certification pathways and securing pilot contracts, even with a technically comparable product.
The most plausible 18-month scenario is one of market fragmentation and validation. The winner will be the company that first secures a flagship hospital deployment. It will use that case study to achieve a key regulatory milestone (like a CE mark for a Class I medical device in Europe). It will then close a Series A to fund commercial expansion. The loser will be any player that remains in perpetual pilot mode. It will fail to convert technical capability into contracted revenue. Thus it will become vulnerable to acquisition by a larger platform seeking the technology without the commercial overhead.
Data Accuracy: YELLOW -- Competitor names are listed in structured facts but lack corroborating public details. BloodFlow's claimed differentiators are from a single secondary source.
Opportunity
PUBLIC The prize for BloodFlow is a foundational position in the clinical decision support software market, specifically for laboratory diagnostics. Successful execution could lead to a high-value, regulatory-cleared asset embedded within the workflows of hundreds of hospitals.
The single largest outcome this company could plausibly become is the default, on-premise AI layer for blood test interpretation within European hospital systems. This outcome is reachable because the company's initial technical wedge targets a critical, high-volume, and repetitive clinical task. A plug-and-play API for EHR integration using the HL7 FHIR standard fits this [Perplexity Sonar Pro Brief, 2025]. By focusing on a narrow, well-defined problem with a standards-based integration approach, BloodFlow aims to reduce the typical friction of hospital IT adoption. The €1.2 million seed funding from a local private equity firm provides the initial capital to navigate the first phase of this regulated path. It is earmarked for pursuing medical device certification [Portugal Startup News, July 2025] [3xP Global, July 2025].
From this initial wedge, several concrete growth scenarios could drive massive scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regulatory-Cleared Platform | BloodFlow obtains CE Mark or similar certification as a Class II medical device for its AI, enabling direct sales to public health systems and use in formal diagnostic pathways. | Successful completion of a retrospective clinical validation study, a stated use of seed funding [Portugal Startup News, July 2025]. | The product is designed for a regulated environment (on-premise, explainable AI), and the funding is explicitly tied to this goal. |
| Pharma Trials Partnership | The platform is adopted by pharmaceutical companies as a tool for patient screening and biomarker monitoring in clinical trials, creating a high-ACV, project-based revenue stream. | A partnership announcement with a mid-sized European CRO or pharma company to pilot the technology. | The company has publicly stated expansion into pharma clinical trials as a target market [Perplexity Sonar Pro Brief, 2025]. |
Compounding success in this market would likely follow a classic land-and-expand flywheel within healthcare. A successful deployment in one hospital department, validated by clinicians, generates case studies and referenceable data. This evidence lowers the perceived risk for adjacent departments within the same hospital network and for peer institutions in the region. Each deployment running on-premise would contribute to a proprietary dataset of localized clinical patterns and outcomes (while preserving patient privacy). This could be used to further refine and validate the AI models. The company's cited focus on "explainable" interpretations is a key enabler for this trust-based expansion [Perplexity Sonar Pro Brief, 2025].
For a sense of the size of the win, consider the trajectory of Babylon Health. Despite its later challenges, it reached a peak public market valuation approaching $4 billion based on its AI-powered primary care and triage platform [Financial Times]. A more focused and capital-efficient comparable could be Butterfly Network. This point-of-care ultrasound company went public via SPAC at a valuation of approximately $1.5 billion. It demonstrates the value of a hardware-software platform in a specific diagnostic niche [Reuters]. If BloodFlow's "Regulatory-Cleared Platform" scenario plays out and it captures a material share of the Western European hospital market for hematology decision support, a valuation in the high hundreds of millions of euros is a plausible outcome (scenario, not a forecast).
Data Accuracy: YELLOW -- Core opportunity thesis is built on company-stated goals and technical approach from a single briefing; market comparables are from public sources.
Sources
PUBLIC
[Portugal Startup News, July 2025] BloodFlow secures €1.2M seed funding to transform blood test analysis | https://portugalstartupnews.com/2025/07/25/bloodflow-secures-e1-2m-seed-funding-to-transform-blood-test-analysis/
[3xP Global, July 2025] 3xP Global Invests in BloodFlow to Advance Real-Time Diagnostic Insights | https://www.3xpglobal.eu/news/3xp-global-invests-in-bloodflow
[The Next Big Idea, 2025] BloodFlow fecha ronda seed de 1,2 milhões para levar IA às análises de sangue | https://thenextbigidea.pt/bloodflow-fecha-ronda-seed-de-12-milhoes-para-levar-ia-as-analises-de-sangue/
[ECO, July 2025] Ex-atleta do Sporting levanta 1,2 milhões para ‘acelerar’ análises ao sangue com inteligência artificial | https://eco.sapo.pt/2025/07/30/ex-atleta-do-sporting-levanta-12-milhoes-para-acelerar-analises-ao-sangue-com-inteligencia-artificial/
[Dealroom, 2025] BloodFlow | https://app.dealroom.co/companies/bloodflow
[LinkedIn, 2025] BloodFlow | https://www.linkedin.com/company/bloodflow2024
[Web Summit, 2025] BloodFlow | Web Summit | https://websummit.com/appearances/lis25/4b90f19b-94d6-4b6a-826b-8e7ae176a170/bloodflow/
[GitHub, 2026] tiagodccosta (Tiago Costa) · GitHub | https://github.com/tiagodccosta
[Perplexity Sonar Pro Brief, 2025] BloodFlow Briefing | [URL not provided in structured facts]
[Grand View Research, 2023] AI in Medical Diagnostics Market Report | [URL not provided in structured facts]
Articles about BloodFlow
- BloodFlow Is Wiring AI Into Hospital Blood Tests — The Lisbon startup's on-premise platform aims to interpret routine lab results in real time, a €1.2M seed bet on a crowded clinical AI field.